CompletedNCT01239030
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
A short description of this study’s research objective has not yet been verified.
Medication studyAges 6–18United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 18 years.
- Listed locations
- Little Rock, United States · Irvine, United States and 14 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateNovember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 230
- Sponsor
- Rhodes Pharmaceuticals, L.P.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT01239030
- Official title
- A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedLittle Rock · Irvine · National City
13 more locations
- Bradenton
- Lauderhill
- Maitland
- North Miami
- Marshfield
- Madison
- Las Vegas
- New York
- Durham
- New Bern
- Cincinnati
- Cleveland
- Wharton
Questions about this study
Who is behind this study?
The study sponsor is Rhodes Pharmaceuticals, L.P.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate Hydrochloride Extended Release Capsules and Placebo.
Who was this study for?
Listed age limits: 6 years to 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
This study is completed in the United States. It is testing time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD.
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
This study is completed. It focuses on ADHD and currently lists study information in the United States.